CoChat

Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer

The DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index.

Abstract

Purpose NK105 is a new drug delivery system formulation for paclitaxel (PTX) whose recommended dose (RD) is 150 mg PTX equivalent/m(2) administered every 3 weeks, as determined in a phase I trial. This study aimed to evaluate the efficacy and safety of NK105 in patients with advanced gastric cancer after failure of first-line chemotherapy. Experimental design Eligible patients had measurable disease and one chemotherapeutic regimen except taxane. NK105 (150 mg PTX equivalent/m(2)) was administered by a 30-minute intravenous infusion every 3 weeks without anti-allergic premedication until disease progression, unacceptable toxicity or patient refusal. The primary efficacy endpoint was best overall response rate (ORR) post baseline. The secondary endpoints were progression-free survival (PFS), time to treatment failure (TTF) and overall survival (OS). All adverse events were reported using CTCAE v3.0. Results Between November 2007 and July 2009, 57 patients were enrolled and 56 were evaluable for efficacy. Two complete responses and 12 partial responses were observed for an ORR of 25%. The median PFS was 3.0 months, the median TTF was 2.8 months, and the median OS was 14.4 months. Drug related toxicity was mainly mild (grades 1-2) to severe (grades 3-4); other data: neutropenia (64.9%); leukopenia (17.5%); lymphopenia (8.8%); neuropathy-sensory (1.8%); fatigue (3.5%); and stomatitis (1.8%). There were no treatment-related deaths. Conclusions This study of NK105 (150 mg PTX equiv…

Overview

Integrity signals

Registry

Crossref · 10.1007/s10637-011-9709-2

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 27 references

Cited by

See all 237

Metadata

Authors
Kato, K., Chin, K., Yoshikawa, T., Yamaguchi, K., Tsuji, Y., Esaki, T., Sakai, K., Kimura, M., Hamaguchi, T., Shimada, Y., Matsumura, Y., & Ikeda, R.
Affiliations
  • National Cancer Centre Japan (JP)
  • Kanagawa Cancer Center (JP)
  • Saitama Cancer Center (JP)
  • Tonan Hospital (JP)
  • National Hospital Organization Kyushu Cancer Center (JP)
  • Saiseikai Kumamoto Hospital (JP)
  • National Cancer Center Hospital (JP)
  • National Cancer Center Hospital East (JP)
  • Nippon Kayaku (Japan) (JP)
Corresponding author
Kato, Ken
Venue
Investigational New Drugs
Published
2011-07-05
Volume
30
Issue
4
Pages
1621-1627
ISSN
  • 0167-6997 (ISSN-L)
  • 1573-0646
OpenAlex
W2014668585
Cited by
237
References
28
Citations by year
2026: 3 · 2025: 7 · 2024: 8 · 2023: 9 · 2022: 7 · 2021: 13 · 2020: 22 · 2019: 16 · 2018: 15 · 2017: 26 · 2016: 28 · 2015: 27 · 2014: 26 · 2013: 21 · 2012: 7
FWCI
14.96
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Investigational New Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
  • Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords
paclitaxel, micellar nanoparticles, drug delivery systems, advanced gastric cancer, recurrent gastric cancer, second-line chemotherapy, taxane-refractory disease, objective response rate, progression-free survival, overall survival, neutropenia, drug toxicity
MeSH terms
Adult, Aged, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Demography, Female, Humans, Male, Micelles, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Stomach Neoplasms, Time Factors, Treatment Outcome, Paclitaxel, Disease-Free Survival, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer. https://app.cochat.ai/papers/10.1007/s10637-011-9709-2
The paper
Kato, K., Chin, K., Yoshikawa, T., Yamaguchi, K., Tsuji, Y., Esaki, T., Sakai, K., Kimura, M., Hamaguchi, T., Shimada, Y., Matsumura, Y., & Ikeda, R. (2012). Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer. Investigational New Drugs. https://doi.org/10.1007/s10637-011-9709-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.